Results for "H.C. Wainwright"

Investment firms including H.C. Wainwright and Citizens have reiterated their bullish stock ratings for Intellia Therapeutics, citing steady progress through the FDA’s priority review pathway.

Protara Therapeutics announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference.

H.C. Wainwright reiterated its Buy rating on both Opus Genetics and PMV Pharmaceuticals, maintaining positive outlooks for the stocks.

Analysts at H.C. Wainwright have reaffirmed their rating on Ionis Pharmaceuticals, pointing to the recent regulatory approval of Zanvastro as a key catalyst for future growth.

Biotechnology firms Longeveron and Scancell are set to showcase their latest developments at the H.C. Wainwright 28th Annual Global Investment Conference. The presentations will highlight their clinical progress and strategic initiatives to institutional investors.

Telix Pharmaceuticals shares surged after completing pivotal clinical trials and advancing its regulatory pathway. The positive data prompted H.C. Wainwright to reaffirm buy ratings on Telix and highlight similar catalysts for peer biotechs like BridgeBio and Alnylam.

Biopharmaceutical company TriSalus Life Sciences confirmed its participation in the H.C. Wainwright conference to highlight drug development milestones.

INVO Fertility announced its participation in the upcoming 28th Annual Global Investment Conference hosted by H.C. Wainwright, where executives will discuss the company's growth strategies and market position.

Investment firm H.C. Wainwright has maintained its buy recommendations for both IREN and Roivant Sciences, highlighting strong growth prospects driven by artificial intelligence revenue and clinical developments. The upgrades reflect analyst confidence in the companies' near-term performance.

NetraMark has confirmed its attendance at the H.C. Wainwright 28th Annual Global Investment Conference, planning to present its business strategy and financial performance to institutional investors.

Multiple investment firms, including DA Davidson, H.C. Wainwright, Stifel, TD Cowen, Wolfe Research, and JPMorgan, have reiterated or initiated stock ratings for various companies. These ratings are based on strong financial results, trial enrollments, earnings outlooks, and market developments.

H.C. Wainwright has increased its stock price targets for both DRDGOLD, following strong results, and Relay Therapeutics, raising its target to $29.

H.C. Wainwright has begun its stock coverage of Alpha Compute, assigning a neutral rating to the company's shares.

H.C. Wainwright has reiterated its 'Buy' rating for Galaxy Digital stock, signaling continued confidence in the company's performance.

H.C. Wainwright has upgraded its rating for Prime Medicine (PRME) to 'Buy,' indicating a more positive investment recommendation for the company.

H.C. Wainwright has increased its price target for Alto Ingredients (ALTO) after the company reported a return to profitability.

H.C. Wainwright has reiterated its "Buy" rating on Iovance Biotherapeutics (IOVA), indicating continued confidence in the company's stock.

Wedbush has cut its price target on CI&T Inc. (CINT) following slight misses in its Q1 results, while DA Davidson has reduced its price target on Salesforce, Inc. (CRM) after its Q1 earnings.

Summit's stock has been downgraded by H.C. Wainwright after the release of new data from Merck regarding its sac-TMT treatment.

H.C. Wainwright has maintained its 'Buy' rating on Hecla Mining (HL) stock. This reflects a continued positive assessment of the mining company's investment prospects.

H.C. Wainwright has reiterated its bullish outlook on Relay Therapeutics, Inc. (RLAY), indicating confidence in the company's prospects.

H.C. Wainwright offers insights into Electrovaya (ELVA), analyzing the company's prospects even after a reported near-term revenue cut.

H.C. Wainwright has raised its price target for Adlai Nortye’s (ANL) lead asset, citing its 'potential best-in-class potency' in a recent analyst report.

H.C. Wainwright has reiterated its 'Buy' rating for Allogene Therapeutics (ALLO), indicating a positive outlook on the company's stock.

H.C. Wainwright has revised its outlook for BioXcel Therapeutics, Inc. (BTAI) following concerns regarding the company's capital structure. The adjustment reflects the analyst firm's updated assessment of the company's financial health.

H.C. Wainwright has begun its coverage of Atlas Critical Minerals, providing initial analysis and recommendations for the company's stock.

H.C. Wainwright expresses a bullish sentiment on Altimmune (ALT) as the company gains increasing attention for its treatments targeting metabolic and liver diseases.

H.C. Wainwright has adjusted its price target for SoundHound AI, Inc. (SOUN) to $20 while maintaining a Buy rating on the stock.

H.C. Wainwright identifies new opportunities for Westwater Resources, Inc. following the termination of an offtake agreement with Fiat Chrysler.

H.C. Wainwright has increased its price target for Oric Pharmaceuticals from $23 to $25.

H.C. Wainwright has initiated coverage of AlphaTON Capital, setting a $2 share price target for the company.

Analysts have upgraded the stock ratings for Robinhood, Roku, and Intellia, citing attractive valuations, new collaborations, and positive clinical trial developments.

Oppenheimer maintained its rating on Braze following Q2 results, while H.C. Wainwright reiterated a buy rating for Inhibrx Biosciences. These analyst actions reflect continued confidence in the companies' prospects despite market volatility.

Biotechnology firm ImageneBio announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference in New York, aiming to engage with investors regarding its pipeline and strategic developments.

Investment banks Jefferies and H.C. Wainwright have raised their stock price targets for Tarsus Pharmaceuticals and Climb Bio, citing improved corporate guidance and promising clinical trial results.

The biotechnology company will showcase its clinical pipeline and strategic initiatives during the 28th Annual Global Investment Conference hosted by H.C. Wainwright.

H.C. Wainwright reiterated a buy rating on Milestone Pharmaceuticals after the company received regulatory approval for its lead asset in China, signaling potential market expansion.

The biotech firm announced it will present at the upcoming H.C. Wainwright investment conference, highlighting its pipeline and business strategy to institutional investors.

Orion announced it will make a formal presentation at the 28th Annual H.C. Wainwright Global Investment Conference, providing investors with insights into its operational milestones and growth trajectory.

H.C. Wainwright upgraded its price target for Generate Biomedicines to $30, citing promising clinical data related to the company's asthma treatment pipeline.

Agricultural equipment maker AGCO and technology firm NetraMark have announced their participation in upcoming global investment conferences hosted by Citi and H.C. Wainwright. Both companies will use the platforms to engage with institutional investors and outline their strategic outlooks.

H.C. Wainwright has updated price targets for Envoy Medical and Electra Battery Materials, while reiterating stock ratings for ClearSign, Lifeward, and Marker Therapeutics, citing various financial updates and growth prospects.

DA Davidson has reiterated its stock ratings for PDF Solutions, citing eProbe growth, and for Boost Run, due to a strong quarter. H.C. Wainwright also reiterated its rating for Tvardi, referencing its UC pivot.

H.C. Wainwright has reiterated its stock rating for CleanSpark, citing the company's ongoing progress in its data center operations as a key factor.

H.C. Wainwright analyst Amit Dayal initiated coverage of American drone-motor company Unusual Machines with a "Buy" rating, citing a "massive procurement tailwind" in modern warfare. The company is expected to benefit from increased demand for drone parts.

H.C. Wainwright has maintained its 'Buy' rating for Vanda Pharmaceuticals (VNDA), citing specific reasons for its continued positive outlook. The firm's analysis suggests the stock remains an attractive investment.

H.C. Wainwright has reaffirmed its 'Buy' rating for Structure Therapeutics (GPCR), signaling continued confidence in the company's stock performance.

Investment firm H.C. Wainwright has maintained its "Buy" recommendation for Precigen (PGEN) stock.

H.C. Wainwright has reiterated its Buy rating on Tempus AI, citing the company's strong revenue growth as a key factor in its positive outlook.

H.C. Wainwright has reduced its price target for Heron Therapeutics, Inc. (HRTX) to $4. The article investigates the factors contributing to this downward revision.

H.C. Wainwright has lowered its price target for Summit Therapeutics Inc. (SMMT) stock.

H.C. Wainwright and Wells Fargo have both increased their price targets for MannKind Corporation (MNKD) shares.

Fortress Biotech is scheduled to participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference.

H.C. Wainwright continues to hold a bullish outlook on Century Therapeutics (IPSC), reaffirming its positive view on the biotechnology company.

H.C. Wainwright has begun coverage of Evotec (EVO) with a 'Buy' rating, indicating a positive outlook on the company's stock.

H.C. Wainwright has increased its price target for Aktis Oncology (AKTS) to $33, reflecting a more favorable outlook for the company's stock.

H.C. Wainwright has reduced its price target for BitFuFu Inc. (FUFU), citing a weaker backdrop in the Bitcoin mining industry.

H.C. Wainwright has reduced its price target for Ur-Energy Inc. (URG) from $2.60 to $2.30, indicating a revised, less favorable assessment of the uranium company's stock.

H.C. Wainwright analysts believe that Roche's recent financial miss does not directly impact the outlook for Olema Pharmaceuticals' OPERA-02 trial.

H.C. Wainwright has reaffirmed its 'Buy' rating on BigBear.ai (BBAI), signaling continued confidence in the company's stock.

H.C. Wainwright has increased its price target for ImmunityBio, Inc. (IBRX) to $15 from $10, maintaining a Buy rating on the company's shares.

H.C. Wainwright has reiterated its 'Buy' rating for Armata Pharmaceuticals, Inc. following a recent FDA approval.

H.C. Wainwright has increased its price target for Alpha Tau from $9 to $12.

H.C. Wainwright has initiated a bullish rating on Hut 8 Corp., indicating a positive outlook for the cryptocurrency mining company.

Oxbridge has announced its attendance at the H.C. Wainwright 28th Annual Global Investment Conference in New York to engage with investors.

ImageneBio, Neurogene, and Compugen have announced their participation in the H.C. Wainwright 28th Annual Global Investment Conference. The event will provide these biotechnology companies with a platform to present their strategies to institutional investors.

H.C. Wainwright has highlighted Fractyl Health as a leading biotechnology stock, citing strong potential in its pipeline.

Investment bank H.C. Wainwright has maintained its buy rating on Legend Biotech stock, citing continued confidence in the company's clinical pipeline and commercial prospects.

Cloud infrastructure firm RedCloud confirmed its participation in the H.C. Wainwright global investment conference, where executives will outline growth strategies and address investor questions.

Several major financial institutions, including Raymond James and Deutsche Bank, have raised their price targets for leading technology and infrastructure companies. Analysts cite accelerating artificial intelligence adoption and robust data center expansion as primary drivers for the upgrades.

Spectral AI, BIO-key, and Unicycive Therapeutics will present their business updates at the H.C. Wainwright 28th Annual Global Investment Conference. The presentations aim to showcase their technological and therapeutic advancements to institutional investors.

Investment firm H.C. Wainwright has maintained its buy rating on the stock of both CRISPR Therapeutics and Gain Therapeutics. The analysts cited strong growth potential within the gene therapy sector to support the positive outlook.

Investment firm H.C. Wainwright maintains its stock rating for Bausch & Lomb, citing recent clinical pipeline developments as key drivers for future valuation.

H.C. Wainwright has reaffirmed its investment ratings for Immuneering, Gossamer Bio, and Voyager Therapeutics, citing promising developments in their respective drug pipelines. The analysts highlighted advancing clinical trials and regulatory milestones as key drivers for future valuation.

Multiple financial institutions have adjusted their stock price targets for various companies, reflecting changes in market valuations, acquisition news, and financial outlooks. These adjustments include both increases and decreases across different sectors.

Stifel and H.C. Wainwright have reiterated their stock ratings for several companies, including Nlight, IDEXX Laboratories, Analog Devices, Veralto, Bitdeer, UroGen Pharma, Bright Minds, Seaport Therapeutics, Ultragenyx, and Zevra Therapeutics. These reiterations are based on various factors such as limited China exposure, data center strength, new deals, and contract agreements.

Several investment firms, including Jefferies, Needham, Scotiabank, UBS, and H.C. Wainwright, have cut price targets for various tech stocks like SanDisk, AppLovin, Oracle, and Circle Internet due to concerns over margins, execution, and AI infrastructure.

H.C. Wainwright expresses a bullish outlook on SAB Biotherapeutics (SABS), setting a $10 price target for the company's stock.

H.C. Wainwright has reiterated its "Buy" rating for Oruka following the news of its acquisition of Apogee. The analyst firm appears optimistic about Oruka's prospects post-acquisition.

H.C. Wainwright has initiated coverage on Brazil Potash with a 'Buy' rating, anticipating the company will evolve into a 'cornerstone supplier.'

H.C. Wainwright has reiterated its Buy rating on GH Research (GHRS), indicating continued confidence in the company's stock performance.

H.C. Wainwright has maintained its bullish outlook on Eton Pharmaceuticals' (ETON) growth strategy. The firm expresses continued confidence in the company's plans for expansion and development.

H.C. Wainwright has identified Uranium Energy (UEC) as a significant investment opportunity within the metals markets, citing its potential for growth.

H.C. Wainwright has lowered its price target for Coinbase Global (COIN) but continues to maintain a 'Buy' rating for the cryptocurrency exchange.

H.C. Wainwright has expressed a bullish sentiment regarding Halozyme Therapeutics, Inc. (HALO), particularly concerning its commercial revenue outlook.

H.C. Wainwright suggests that Ur-Energy Inc. (URG) is well-positioned to capitalize on a tight uranium market, indicating potential growth for the company.

H.C. Wainwright has reiterated its 'Buy' rating for Legend Biotech, indicating continued confidence in the company's financial performance and future prospects.

H.C. Wainwright has initiated coverage of Generate Biomedicines (GENB) with a 'Buy' rating. This new analyst report offers a positive investment perspective on the biotechnology firm.

Enliven (ELVN) has seen its price targets raised by H.C. Wainwright and Mizuho, reflecting positive analyst sentiment.

H.C. Wainwright has reiterated its bullish outlook on AtaiBeckley (ATAI), indicating confidence in the company's stock performance.

H.C. Wainwright has increased its price target for Lexicon Pharmaceuticals, Inc. (LXRX) from $4 to $6, maintaining a 'Buy' rating.

H.C. Wainwright increased its price target for First Majestic Silver Corp. following the company's strong financial performance in its latest quarter.

H.C. Wainwright has increased its price target for CG Oncology, Inc. (CGON) to $80, while maintaining a Buy rating on the company's stock.

H.C. Wainwright has lowered its price target for Rhythm Pharmaceuticals to $110 from $125.

Multiple financial institutions have updated their ratings and price targets for various companies, including Wells Fargo raising Globe Life (GL) target, Bank of America downgrading Fox (FOX), KeyBanc raising Zoom (ZM) target, H.C. Wainwright raising United Therapeutics (UTHR) target, Bernstein upgrading Newmont (NEM), analysts maintaining a hold on PepsiCo (PEP), Truist raising BILL Holdings (BILL) target, Barclays reiterating a buy on Charles Schwab (SCHW), Barclays upgrading Etsy (ETSY) and Truist raising its target, Goldman Sachs cutting Pinterest (PINS) target and RBC downgrading shares, Wells Fargo maintaining a hold on Hewlett Packard Enterprise (HPE), UBS upgrading Southwest Airlines (LUV), Stifel raising Triple Flag Precious Metals (TFPM) target, Barclays raising Phillips 66 (PSX) target, and Veritas downgrading Suncor Energy (SU).

H.C. Wainwright has raised its price target for Palvella Therapeutics from $200 to $255.

H.C. Wainwright has reiterated its 'Buy' rating on Beam Therapeutics (BEAM) following the FDA's expedited approval of BEAM-302.